Skip to search formSkip to main contentSkip to account menu

zirconium-89-trastuzumab

Known as: (89)Zr-trastuzumab, 89Zr-trastuzumab, Zirconium Zr 89 Trastuzumab 
A radioimmunoconjugate containing the recombinant humanized monoclonal antibody trastuzumab labeled with the radioisotope zirconium Zr 89 with… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Antibodies, Monoclonal, Humanized

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
The Era of Therapeutic Biosimilars Has Arrived: What You Need to Know.
Although complex, biologic agents are key components of modern therapy in multiple disciplines, particularly oncology. However… 
2016
2016
Abstract P4-14-01: Trastuzumab emtansine improves overall survival versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer: Final results from the…
Introduction T-DM1 is indicated for the treatment of advanced HER2-positive MBC in patients who previously received trastuzumab… 
2015
2015
Targeting of EGFR and HER 2 with therapeutic antibodies and siRNA A comparative study in glioblastoma cells
variety of human malignancies and both are functionally involved in the molecular pathogenesis of malignant gliomas. Material and… 
2015
2015
Abstract 641: Trastuzumab-dolaflexin, a highly potent Fleximer-based antibody-drug conjugate, demonstrates a favorable therapeutic index in exploratory toxicology studies in multiple species
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA Antibody-drug conjugates (ADCs) represent a… 
2014
2014
Abstract 2645: Advantages of polyacetal polymer-based ADCs: Application to low expression targets
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA The application of biodegradable polymers to antibody-drug… 
2013
2013
H4octapa-trastuzumab: An acyclic chelator-immunoconjugate with superior properties to DOTA for In-111/Lu-177 imaging and therapy
2011
2011
P1-12-19: Phase I Study of Single Agent Trastuzumab Emtansine in Japanese Patients with Human Epidermal Growth Factor Receptor2 (HER2)-Positive Metastatic Breast Cancer (JO22591).
Background Trastuzumab emtansine (T-DM1), first-in-class anti-HER2 antibody-drug conjugate (ADC) is under development for the… 
2011
2011
P1-12-07: Pharmacokinetics (PK) of Trastuzumab Emtansine and Paclitaxel or Docetaxel in Patients with HER2−Positive MBC Previously Treated with a Trastuzumab-Containing Regimen.
Background: Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate composed of trastuzumab, DM1 (a potent cytotoxic tubulin… 
2011
2011
Trastuzumab emtansine, tumor-activated prodrug (TAP) immunoconjungate, oncolytic
Review
2002
Review
2002
From the Food and Drug Administration.
  • C. Gottlieb
  • Journal of the American Medical Association (JAMA…
  • 2002
  • Corpus ID: 31318586
The FDA recently approved the first biosimilar for patients with certain breast or stomach cancers. Marketed as Ogivri… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)